Key result
Non-metastatic solid tumors show similar CABG mortality to non-cancer controls but higher hemorrhage risk.
Why the study?
Previous studies showed mixed outcomes for cancer patients after cardiac surgery, but the impact of non-metastatic malignant solid tumors on short-term CABG outcomes remains unclear.
Does CABG in patients with non-metastatic malignant solid tumors result in similar in-hospital mortality compared to patients without cancer?
Cohort (n=166,490)
Yes
Does CABG in patients with non-metastatic malignant solid tumors result in similar in-hospital mortality compared to patients without cancer?
Absolute Event Rate: 2.25% vs 2.16%
p-value: p=0.80
Patients with non-metastatic malignant solid tumors undergoing CABG have comparable in-hospital mortality to those without cancer, though they face a higher risk of postoperative bleeding.
Supports considering CABG in non-metastatic solid tumors with bleeding vigilance; leaves open randomized confirmation of safety.
INTRODUCTION: Previous studies found that patients with a history of cancer either have similar outcomes or face an increased risk of early morbidity following cardiac surgery. However, the applicability of these findings to clinical practice may be constrained by the heterogeneity of cancer patients. To refine our understanding, this study focuses specifically on the in-hospital outcomes of patients with non-metastatic malignant solid tumors (NMST) undergoing coronary artery bypass grafting (CABG). METHODS: Patients who underwent CABG were identified in National/Nationwide Inpatient Sample from Q4 2015-2020. Exclusion criteria included age < 18 years, concomitant procedures, and other malignancies. A 1:3 propensity-score matching was employed to address differences in demographics, socioeconomic status, primary payer status, hospital characteristics, comorbidities, and admission status between patients with and without NMST. In-hospital outcomes after CABG were evaluated. RESULTS: There were 2,139 patients with NMST who underwent CABG and who were matched to 6,580 out of 164,351 patients without NMST. Patients with and without NMST had comparable mortality (2.25% vs. 2.16%, P=0.80). However, NMST patients have a higher risk of hemorrhage/hematoma (63.48% vs. 58.27%, P<0.01) and a higher rate of transfer out (28.75% vs. 25.36%, P<0.01). In addition, patients with NMST had longer time from admission to operation (P<0.01), a longer length of stay (P<0.01), and higher hospital charges (P<0.01). CONCLUSION: Patients with NMST have comparable short-term outcomes after CABG, except for a higher risk of postoperative bleeding. Thus, CABG could be performed safely for NMST patients, despite long-term prognosis of these patients may require further investigation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) conducted a cohort in Coronary artery disease requiring CABG (n=166,490). Non-metastatic malignant solid tumors vs. Patients without non-metastatic malignant solid tumors was evaluated on In-hospital mortality (p=0.80). Patients with non-metastatic malignant solid tumors undergoing coronary artery bypass grafting had comparable in-hospital mortality to those without tumors (2.25% vs. 2.16%), but a significantly higher risk of hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: